Ubs Group Ag Freeline Therapeutics Holdings PLC Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.42 - $0.63 $7,108 - $10,663	-16,926 Reduced 3.27%	500,000 $230,000
Q4 2022 Feb 08, 2023	BUY	$0.46 - $0.73 $334 - $530	727 Added 0.14%	516,926 $248,000
Q3 2022 Nov 10, 2022	BUY	$0.69 - $1.1 $8,046 - $12,827	11,661 Added 2.31%	516,199 $361,000
Q2 2022 Aug 10, 2022	SELL	$0.69 - $1.12 $121 - $197	-176 Reduced 0.03%	504,538 $439,000
Q1 2022 May 16, 2022	BUY	$0.92 - $2.03 $464,336 - $1.02 Million	504,714 New	504,714 $565,000
Q4 2021 Feb 14, 2022	SELL	$1.97 - $3.45 $985 - $1,725	-500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $1,520 - $4,450	500 New	500 $2,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.